ADARx Pharmaceuticals, Inc.
corporate_fare Company Profile
ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 8 items for ADRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 8 most recent items scored 7 or higher, the top rating is 8/10, with 2 rated 8 or above. Recent SEC coverage for ADRX spans 8-K, 4, 424B4.
Recent high-impact activity:
- ADARx Posts Q3 Loss, $901M Cash Into 2030, New Onvuzosiran Phase 2a Data
- ADARx Posts $901M Cash Pile, Says Funding Lasts Into 2030
- ADARx Fully Exercises Underwriters' Option, IPO Proceeds Reach $513M
- OrbiMed Buys $16.15M in ADARx IPO, Converts 23.3M Preferred Shares
- Director George Simeon Buys $27.2M of ADARx Stock at IPO Price
Short Interest & Short Volume
5.02 days to coverFINRA reported short interest of 1,801,373 shares in ADRX as of the October 30, 2026 settlement, a 5.4% decrease from the prior period — about 5.0 days to cover at its recent average daily volume. On November 20, 2026, 60.5% of ADRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ADRX, detected from its recent SEC filings · based on capital-structure filings through 2026-09-26.
Upsized IPO Priced at $17.00/Share · AbbVie Concurrent Private Placement
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →